Paul Aridgides

Paul Aridgides

Auto-generated profile, based on publicly available information

Paul Aridgides

Department of Radiation Oncology, Upstate Medical University , Syracuse, NY, (P.A.)

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in Neuro-Oncology
Verified
Journal Article
Closed access
CMClaire Mazewski
Claire Mazewski
SLSarah E S Leary
Sarah E S Leary
Guolian KangGuolian Kang
Guolian Kang
BLBryan K Li
Bryan K Li
SKStewart Kellie
Stewart Kellie
AHAnnie Huang
Annie Huang
Background: Embryonal brain tumors are the leading cause of cancer death in young children. Methods: ACNS0334 was a phase 3 randomized study evaluating high-dose methotrexate in young children < 36 months old with newly diagnosed high-risk embryonal brain tumors. Treatment included 3 cycles of induction chemotherapy with or without methotrexate followed by 3 cycles of high-dose consolidation chemotherapy with hematopoietic stem-cell infusion. Primary endpoint was complete response (CR) at the end of therapy. Secondary endpoints included a comparison of event-free survival (EFS) between arms and to historical controls. Molecular characterization was conducted retrospectively. Tests of significance were one-sided. Results: Of 77 eligible patients, 59 with detectable disease were evaluated for response and 28 (47.5%) achieved CR, 15/30 (50%) treated with methotrexate compared to 13/29 (45%) without methotrexate (P = 0.35). For MB, CR was 12/19 (63%) with methotrexate compared to 6/20 (30%) without methotrexate (P = 0.039). Considering molecular diagnosis, all SHH MB (n = 11) were survivors. Five-year EFS was 70% (90% CI: 39.6–87.2) for 10 Group 3 MB with methotrexate versus 33.3% (90% CI: 15.0–52.9) for 15 without (P = 0.037). In other embryonal tumors, CR was 3/11 (27%) with methotrexate compared to 7/9 (78%) without (P = 0.99). No benefit with methotrexate was observed for Embryonal Tumor with Multilayered Rosettes (n = 14, EFS 20.0% [90% CI: 1.8–52.5] with methotrexate versus 33.3% [90% CI: 10.8–58.1] without, P = 0.58), or pineoblastoma (n = 9, EFS 16.7% [90% CI: 1.6–46.1] with methotrexate versus 0% without, P = 0.52). Conclusions: The addition of methotrexate to intensive chemotherapy improved CR and EFS for young children with high-risk Group 3 MB, but not other diagnoses.

26 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
OOOtasowie Odiase
Otasowie Odiase
LNLindsay Noah-Vermillion
Lindsay Noah-Vermillion
BSBrittany A. Simone
Brittany A. Simone
PAPaul D. Aridgides
Paul D. Aridgides
In 2011 the Food and Drug Administration (FDA) approved anti-vascular endothelial growth factor (VEGF) therapy, bevacizumab, for intractable melanoma. Within the year, immunotherapy modulators inhibiting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) were approved in addition to programmed death-ligand 1 (PD-L1) antibodies in 2012. Since then, research showing the effectiveness of targeted therapies in a wide range of solid tumors has prompted studies incorporating their inclusion as part of upfront management as well as refractory or relapsed disease. For treatment of cervical cancer, which arises from known virus-driven oncogenic pathways, the incorporation of targeted therapy is a particularly attractive prospect. The current standard of care for locally advanced cervical cancer includes concurrent platinum-based chemotherapy with radiation therapy (CRT) including external beam radiation therapy (EBRT) and brachytherapy. Building upon encouraging results from trials testing bevacizumab or immunotherapy in recurrent cervical cancer, these agents have begun to be incorporated into upfront CRT strategies for prospective study. This article will review background data establishing efficacy of angiogenesis inhibitors and immunotherapy in the treatment of cervical cancer as well as results of prospective studies combining targeted therapies with standard CRT with the aim of improving outcomes. In addition, the role of immunotherapy and radiation on the tumor microenvironment (TME) will be discussed.

1 August 2016 in Thoracic Surgery Clinics
Verified
Journal Article
Closed access
PAPaul Aridgides
Paul Aridgides
JBJeffrey Bogart
Jeffrey Bogart

1 November 2013 in Clinical Lung Cancer
Verified
Journal Article
Closed access
PAPaul D. Aridgides
Paul D. Aridgides
AJAdam Janik
Adam Janik
JBJeffrey A. Bogart
Jeffrey A. Bogart
SDSteven Duffy
Steven Duffy
PRPaula Rosenbaum
Paula Rosenbaum
AGAjeet Gajra
Ajeet Gajra

22 September 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
PAPaul Aridgides
Paul Aridgides
GJGeert O. Janssens
Geert O. Janssens
SBSteve Braunstein
Steve Braunstein
SCShauna Campbell
Shauna Campbell
MPMatthew Poppe
Matthew Poppe
DHDaphne Haas‐Kogan
Daphne Haas‐Kogan

1 January 2016 in Journal of Contemporary Brachytherapy
Verified
Journal Article
Open access
PAPaul Aridgides
Paul Aridgides
BOBenjamin Onderdonk
Benjamin Onderdonk
MCMary Cunningham
Mary Cunningham
EDEmily Daugherty
Emily Daugherty
LDLingyun Du
Lingyun Du
SHSeung Shin Hahn
Seung Shin Hahn
Purpose: The study assessed the outcomes of patients at a single institution with locally advanced primary and recurrent pelvic malignancies treated with interstitial high-dose-rate (HDR) or low-dose-rate (LDR) brachytherapy (BT), using a modified Syed-Neblett template. Material and...